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Mesenchymal epithelial transition factor receptor (Met) is a receptor tyrosine kinase that plays a critical role in
promoting cancer cell malignant progression. Met is activated by its ligand hepatocyte growth factor (HGF).
HGF-dependent Met activation plays an important role in stimulating epithelial-mesenchymal transition (EMT) in
tumor cells, resulting in increased tumor cell proliferation, survival, motility, angiogenesis, invasion, and metastasis.
The HGF/Met axis has thus attracted great interest as a potential target in the development of novel cancer therapies.
In an effort to suppress tumor cell malignant progression, efforts have been made to develop agents capable of inhibiting
inhibit Met-induced EMT, including specific Met tyrosine kinase inhibitors, HGF antagonists that interfere with HGF binding
to Met, and antibodies that prevent Met activation and/or dimerization. Tocotrienols, a subgroup within the vitamin E
family of compounds, display potent anticancer activity that results, at least in part, from inhibition of HGF-dependent
Met activation and signaling. The present review will provide a brief summary of the increasing importance of the
HGF/Met axis as an attractive target for cancer chemotherapy and the role of tocotrienols in suppressing Met activation,
signaling and HGF-induced EMT in breast cancer cells. Evidence provided suggests that γ-tocotrienol therapy may afford
significant benefit in the treatment of breast cancers characterized by Met dysregulation.
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Traditional cancer chemotherapeutic agents typically ex-
hibit non-selective activity and often produce low re-
sponse rates and severe toxic side effects in patients [1].
Thus, there is currently great interest in developing
novel therapeutic agents that target signaling molecules
involved in the growth, survival and progression of ma-
lignant cells with high specificity. The advantage of such
targeted therapies is enhanced efficacy and a reduction
in adverse side effects. A promising intracellular target
is the receptor tyrosine kinase, mesenchymal epithelial
transition factor (Met). Expressed in cells of epithelial
origin, Met is activated by its ligand hepatocyte growth
factor (HGF; scatter factor), which is produced by mes-
enchymal cells [2,3]. HGF/Met signaling is critical for
epithelial-mesenchymal interactions underlying normal
functions including cell migration, morphology, cell di-
vision during tissue remodeling and repair, and organo-
genesis during embryonic development [3,4]. However,Correspondence: sylvester@ulm.edu
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in any medium, provided the original work is pMet is also implicated in malignant progression. Exces-
sive or unregulated tumor cell Met activity is associated
with poor patient prognosis owing to aggressive malignant
phenotype typified by enhanced angiogenesis, invasion
and metastasis [5-8].
HGF-dependent activation of Met leads to receptor
dimerization, tyrosine autophosphorylation, and initiation
of down-stream signaling, including activation of MAPK,
PI3K/Akt, and STAT pathways, all of which play an im-
portant role in cancer cell proliferation and survival
[7,9,10]. However, oncogenic mutations can result in
Met overexpression and/or aberrant signaling that can
lead to epithelial-to-mesenchymal transition (EMT)
[8,11,12]. Epithelial cells that undergo EMT lose epi-
thelial cell characteristics and acquire a mesenchymal
phenotype characterized by migratory and invasive
characteristics [9,12,13]. Epithelial and mesenchymal cells
differ regarding function, morphology and expression of
phenotype-specific protein cell markers. Epithelial cells
express high levels of cytokeratin, E-cadherin, and β-
catenin proteins, whereas N-cadherin, fibronectin and
vimentin proteins occur at high levels in mesenchymalpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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cancer stem cell-like properties that are associated with
enhanced malignant potential and progression [19].
Tumors exhibiting rapid growth often face insufficient
blood flow to meet their high oxygen demands, but are able
to adapt to hypoxic conditions by altering metabolism
and phenotypic functions [20]. A typical compensatory re-
sponse to hypoxia is increased production of hypoxia-
inducible factor-1 (HIF-1), which reportedly increases
HGF-dependent MET expression and signaling [21,22].
Since cancer cell invasion and metastasis are primary
causes of cancer patient death, therapeutic strategies that
target and suppress malignant progression may significantly
improve patient survival. Thus, HGF-dependent Met acti-
vation has emerged as an attractive target for therapeutic
intervention because of its role in promoting tumor cell
EMT, angiogenesis, proliferation and survival [23].
Various approaches have been used to inhibit Met
activation and signaling, including agents that inhibit tyro-
sine kinase activity (K252a, SUii274, PHA-665752, and
PF2341066), neutralizing antibodies (anti-HGF antibodies)
and competitive antagonists (NK4 and uncleavable HGF)
that interfere with HGF binding and activation of Met,
and agents that block HGF binding to Met and/or Met
receptor dimerization (anti-Met antibodies) [4]. Recent
investigations also show that certain natural products dis-
play potent inhibitory effects against Met activation and
signaling. Tocotrienol, a rare natural form of vitamin E, is
one such natural product that potently inhibits Met acti-
vation and signaling and displays potent anticancer acti-
vity at treatment doses that have minimal or no effect on
normal cell function or viability [24,25]. The present re-
view will present a brief summary of evidence supporting
the HGF/Met axis as a plausible target for cancer chemo-
therapy, and the role of tocotrienols in suppressing Met
activation, signaling and HGF-induced EMT.
Review
Met activation and signaling
Met is expressed exclusively in epithelial cells, whereas
its natural ligand HGF is produced solely by mesenchy-
mal cells [3,4,26-29]. Mediated by paracrine mechanisms
[30], HGF activation of Met is intimately involved in
epithelial cell phenotypic morphology and behavior, in-
cluding cell proliferation, motility, invasion, angiogen-
esis, and branching tubulogenesis [9,10,31-33]. All these
events occur during normal events such as embryogen-
esis, and tissue remodeling, regeneration, and repair in
adults [13,26,34].
Different biological effects of Met signaling are directly
associated with activation of specific intracellular path-
ways. HGF-induced cell proliferation is mediated by acti-
vation of the MAPK cascade [35], whereas activation of
the PI3K/Akt pathway promotes cell survival and preventscaspase-dependent apoptosis [9,10,36]. The ability of HGF
to induce epithelial cell morphological changes and motility
requires disruption of cell-to-cell adhesion and dissociation
of the basal lamina from the extracellular matrix [13,37].
HGF-induced cell scattering and invasion is achieved
by activation of several different signaling molecules
and pathways, including PI3K, Rac and Rho [13,37].
Additionally, Met activation can stimulate vascular
endothelial growth factor (VEGF) production to en-
hance angiogenesis [10,26]. Met forms heterodimers
with other receptor tyrosine kinases including mem-
bers of the epidermal growth factor (EGF) receptor
family; this crosstalk between Met and other growth
factor receptors permits integration of signals during
the process of phenotypic change [38].
Met mutations, overexpression and/or dysregulation
commonly occur in a wide variety of cancers, characteris-
tics that are associated with promotion of cancer progres-
sion, including tumor cell proliferation, survival, motility,
EMT, angiogenesis, invasion and metastasis [9,10,39]. The
majority of mutations that result in constitutive activation
of Met occur in the receptor’s cytoplasmic tyrosine kinase
domain [31], while mutations in the autoregulatory do-
main of the receptor allow for persistent and unattenuated
responsiveness to HGF stimulation [13,35]. Overexpres-
sion of HGF can also induce oncogenic effects through
over-stimulation of the non-mutated Met receptor, which
can lead to enhanced tumor cell progression and malig-
nant phenotype [10,40,41]. Enhanced HGF expression is
specifically implicated as a promoter and risk factor in
breast cancer [42]. Previous studies show that elevated
circulating HGF levels correlate with lower survival
rates and increased risk of metastasis in breast cancer
patients [43,44]. Occurrence of high levels of HGF in
breast cancer biopsies is associated with an aggressive
malignant phenotype [5]. Studies show that Met is over-
expressed in nearly 30% of all breast cancers and is a
strong independent predictor of poor patient prognosis
and survival [30,43]. Microarray analysis of tissue ob-
tained from breast cancer patients shows that elevations
in Met expression occur in a significant percentage of
EGFR/HER2 negative tumors [30].
Inhibitors of HGF-induced Met activation and signaling
Since Met plays an important role in malignant pro-
gression, it has emerged as a practical target in cancer
chemotherapy, with various strategies currently under
development to inhibit Met activation and signaling.
Agents that decrease receptor tyrosine kinase activity
include low molecular weight molecules that block
ATP binding to Met’s catalytic, thereby inhibiting re-
ceptor autophosphorylation and recruitment of mole-
cules associated with downstream signaling [4]. Several
Met tyrosine kinase inhibitors, including K252a,
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studied extensively [4]. While these agents are reported
to be very effective in suppressing kinase activity, their
clinical usefulness is somewhat limited because they do
not inhibit Met transcription and translation [45]. Sub-
sequently, a second generation of agents developed in
recent years are currently being tested in clinical trials.
The use of Met tyrosine kinase inhibitors and other
Met inhibitors in the treatment of human cancers has
been recently reviewed in detail [46]. The inhibitory
actions of these agents are summarized in Figure 1.
Agents that inhibit HGF include NK4, anti-HGF neu-
tralizing antibodies, and an uncleavable HGF agonist.
NK4 is a HGF-like ligand that binds to Met without
activating the receptor [47], whereas the neutralizing
anti-HGF antibodies act on various regions of the HGF
molecule to prevent HGF binding to and activation of
Met [48]. The uncleavable form of HGF is not biologically
active, but interacts with the ligand binding site on Met to
block receptor activation [49,50]. However, HGF inhibi-
tors have also been found to have somewhat limited use
because they only suppress HGF-dependent Met activa-
tion and are not effective against mutated Met receptors
that are constitutively active (4).Figure 1 Schematic representation of the Met receptor and therapeutic
activation and signaling in cancer. The Met receptor has an extracellular
the tyrosine kinase domain and autophosphorylation sites that are essentia
receptor dimerization and recruitment of adaptor (GAB1, Grb2, Shc) and sig
signaling promotes cell proliferation, altered cytoskeletal function, decrease
and enhanced DNA transcription. Anti-HGF approaches to inhibit Met sign
that block HGF binding to the Met receptor. A second approach includes t
Met dimerization. Another approach is the use of specific Met tyrosine kina
Tocotrienols have also been found to be potent inhibitors of Met activation
not completely understood at present. Targeting aberrant Met signaling in
with tumor cell proliferation, motility, viability, morphology and epithelial-toTocotrienol inhibition of HGF-induced Met activation and
epithelial-mesenchymal transition
Vitamin E represents a family of compounds that is di-
vided into structurally similar tocopherol and tocotrienol
subgroups [51,52]. These subgroups differ as tocopherols
have a saturated, whereas tocotrienols have an unsatur-
ated phytyl chain attached to a chromane ring structure
[51,52], as shown in Figure 2. However, only tocotrie-
nols displays potent anticancer activity at treatment
doses that do not affect normal cell growth or viability
[53,54]. Individual isoforms (α, β, γ, and δ) of tocoph-
erols and tocotrienols are differentiated by degree of
chromane ring methylation (Figure 2). Previous studies
show that antiproliferative and apoptotic effects of toco-
trienols are mediated, at least in part, by their ability to
inhibit EGF receptor family member activation and sig-
nal transduction [55-57]. γ-Tocotrienol inhibition of
mammary tumor cell growth is mediated by suppression
of receptor tyrosine kinase activity of HER3/ErbB3,
HER4/ErbB4, and to a lesser extent HER2/ErbB2, but
not HER1/ErbB1, and attenuation of receptor down-
stream pathways that include MAPK, PI3K/Akt, STAT,
and NFκB signaling [55-57]. Subsequent work demon-
strated that γ-tocotrienol is also a powerful inhibitor ofstrategies currently being developed to inhibit HGF-dependent Met
α-chain that binds HGF and a transmembrane β-chain that contains
l for interacting with substrates. Activation of Met by HGF leads to
naling (Ras/MAPK, PI3K/Akt, Src, STAT, Shp2) proteins. Downstream
d cellular adhesion, increased cellular invasion, decreased apoptosis
aling include anti-HGF antibodies that neutralize HGF and antagonists
he use of anti-Met antibodies that prevent HGF binding to Met or
se inhibitors that prevent receptor second messenger signaling.
and signaling, but the exact mechanism mediating these effects are
cancer cells can inhibit of downstream signaling pathways involved
-mesenchymal transition.
Figure 2 Generalized chemical structure of natural tocopherols and tocotrienols that make up the vitamin E family of compounds.
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ing [24,25].
Studies using + SA mammary tumor cells maintained in
serum-free defined media containing HGF as a mitogen
show that HGF induces a dose-responsive increase in
growth and corresponding increase in Met autophospho-
rylation, whereas combined treatment with γ-tocotrienol
blocks these effects [24]. In addition, γ-tocotrienol treat-
ment is reported to significantly reduce total Met levels in
these cells. In contrast, similar treatment with growth-
inhibiting doses of the Met tyrosine kinase inhibitor
SU11274 inhibits HGF-dependent Met autophosphoryl-
ation, but has no effect on cellular levels of Met [24]. Simi-
larly, tumor cells transfection with Met specific siRNA
significantly inhibits HGF-dependent growth [24].
Subsequent studies confirm and extend these findings
in human breast cancer cell lines [25]. Results show that
treatment with either γ-tocotrienol or the Met tyrosine
kinase inhibitor SU11274 alone induces dose-dependent
inhibition in estrogen receptor- positive MCF-7 and es-
trogen receptor negative MDA-MB 231 human breast
cancer cells. However, combined treatment with subef-
fective doses (non-growth inhibiting) of γ-tocotrienol
and SU11274 results in synergistic inhibition of MCF-7 and
MDA-MB-231 cancer cells, while these same treatments
have no effect on growth or viability of immortalized
normal MCF10A human mammary epithelial cells [25].
These finding demonstrate that tocotrienol treatment
alone or in combination with Met inhibitors selectively
inhibits growth of breast cancer cells without affecting
normal cell growth or viability. In addition, combination
treatment significantly reduces Met autophosphorylation
and phosphorylation (activation) of receptor substratesinvolved in downstream signal transduction, including
STAT1, STAT5, Akt, and NFκB (26), and significantly in-
hibits breast cancer cell motility and migration as deter-
mined by wound healing assay [25].
HGF-dependent Met activation in transformed epithelial
cells promotes expression of a malignant mammary epithe-
lial phenotype [8]. Met-induced tumor cell progression to a
malignant phenotype is a multi-step process, characterized
by the loss of epithelial polarity, loss of cell to cell adhe-
sions, degradation of basal lamina, and increased cell
migration and invasion [3,4,26-29]. An initial step in Met-
induced malignant progression is EMT (Figure 3). EMT is
essential for migration of tumor cells from the site of the
primary tumor, invasion into surrounding tissues and
entrance into the systemic circulation [6,8,11,12,14-18].
HGF-dependent activation of Met signaling shows a direct
correlation with a reduction of cadherin-based adherens
junctions, followed by loss of E-cadherin and cytokeratins
8/18 expression, and increased expression of mesenchymal
proteins such as vimentin [6,8,11,12,14-18]. Epithelial cells
that undergo EMT lose epithelial cell characteristics and
acquire a mesenchymal phenotype, including changes in
their morphology, increased motility and invasiveness [12].
Since combined treatment with low dose of γ-tocotrienol
and SU11274 has profound inhibitory effects on tumor cell
growth and HGF-dependent Met activation and signaling,
additional studies aimed to determine effects of these
agents on breast cancer cell epithelial and mesenchymal cell
marker expression. Results show that neoplastic mammary
epithelial cells grown in serum-free culture medium con-
taining HGF as a mitogen display a strong transition from
epithelial to mesenchymal cell phenotype, as evidenced
by low epithelial marker and high mesenchymal marker
Figure 3 Schematic representation of HGF/Met-mediated
epithelial mesenchymal transition (EMT) and promotion of
malignant progression. HGF-mediated Met activation and signaling
can induced multiple pathways that are involved in stimulating
cancer cell proliferation, survival, motility, angiogenesis, invasion and
metastasis. Normal epithelial cells display a highly differentiated
morphology characterized by a single layer of cells anchored by their
basal lamina to the extracellular matrix. Aberrant Met activity will
stimulate cell proliferation and EMT that ultimately results in changes
in morphology and behavior, characteristic of a mesenchymal-like
phenotype. EMT allows cancerous epithelial cells to become more
mobile, invasive and metastatic in nature.
Sylvester Clinical and Translational Medicine 2014, 3:30 Page 5 of 9
http://www.clintransmed.com/content/3/1/30protein expression [25]. Specifically, cells display rela-
tively low levels of the epithelial cell protein markers
E-cadherin, β-catenin, cytokeratin-8, and cytokeratin-18,
and a relatively high levels of the mesenchymal proteinmarker, vimentin [25]. These studies also show that treat-
ment with subeffective (non-growth inhibiting) dose of
γ-tocotrienol or SU11274 alone causes only a slight reduc-
tion in EMT, characterized by a slight increase in the level
of some epithelial markers (cytokeratin-8 and cytokeratin-
18), but little or no change in vimentin expression [25].
However, combined treatment with these subeffective
doses of γ-tocotrienol and SU11274 results in reversal
of EMT, as demonstrated by changes in cell marker
expression including augmentation of epithelial pro-
tein markers E-cadherin, β-catenin, cytokeratin-8, and
cytokeratin-18, and corresponding reduction in mesen-
chymal protein marker (vimentin) expression [25]. Treat-
ment effects on epithelial and mesenchymal cell marker
expression in mammary cancer cells are shown in Figure 4.
Taken together, these findings provide evidence that
γ-tocotrienol inhibits HGF-dependent Met activation
and signaling and causes reversal of EMT. However, add-
itional studies are required to verify that these effects
obtained in vitro occur in in vivo.
Met expression is also responsive to various types of
stress, particularly low oxygen tension or hypoxia [22].
Rapidly-growing solid tumors often display insufficient
blood flow and oxygen deficiency within deep inner re-
gions of the tumor. In response to hypoxic conditions,
tumor cells are able to adapt by altering metabolism and
phenotypic characteristics [20,58]. This compensatory
response to hypoxia is mediated by increased production
of hypoxia-inducible factor-1 (HIF-1), a transcription
factor that promotes cell survival during hypoxic condi-
tions [21,59-61]. HIF-1 is a heterodimer consisting of
HIF-1α and HIF-1β subunits [21]. HIF-1β is constitu-
tively expressed in most cells, whereas HIF-1α is indu-
cible and is characteristically over-expressed in cancer
cells during hypoxic conditions [21]. Overexpression of
HIF-1α is also associated with elevated production of
VEGF, a growth factor that promotes tumor angiogen-
esis, invasion and metastasis [62]. Studies show that
during hypoxia, Met expression is increased through
binding of HIF-1 to the Met promoter region to amplify
HGF-dependent Met activation and signaling, facilitating
cancer cell malignant progression [22]. Recent studies
show that during hypoxic conditions, natural and semisyn-
thetic derivatives of tocotrienols inhibit mammary tumor
cell expression of HIF-1, Akt/mTOR activity and VEGF
production in vitro and in vivo [63]. Although these
findings suggest that tocotrienol treatment can also act to
suppress the compensatory mechanisms that promote
tumor growth and survival during hypoxic conditions,
possibly through the inhibition of HGF/Met activation,
additional studies are required to establish a direct rela-
tionship. The effects of δ-tocotrienol and its oxazine de-
rivation on HIF-1α expression in mammary tumor cells
during CoCl2-induced hypoxia are shown in Figure 5.
Figure 4 Effects of γ-tocotrienol (γT3) and/or the Met tyrosine kinase inhibitor, SU11274 (SU), on the expression of major epithelial and
mesenchymal cellular protein markers in + SA mammary tumor cells. Cells were incubated with control or treatment media containing
subeffective doses of γ-tocotrienol (2 μM) and SU11274 (3 μM) either alone or in combination containing 10 ng/ml HGF as a mitogen for 3-days.
(A) Afterwards, whole cell lysates were prepared and subjected to polyacrylamide gel electrophoresis and Western blot analysis for E-cadherin,
β-catenin, cytokeratin-8, cytokeratin-18, and vimentin. α-Tubulin was visualized to ensure equal sample loading in each lane. Scanning densitometric
analysis was performed for each blot to visualize the relative levels of proteins. Integrated optical density of each band was normalized with their
corresponding α-tubulin and control treatment bands and shown in bar graphs. Vertical bars indicate the fold-change in protein levels in various
treatment groups ± SEM as compared with their respective vehicle-treated control group. *P < 0.05 as compared to their respective vehicle-treated
control group. (B) Treatment effects on immunocytochemical fluorescence staining of epithelial and mesenchymal markers in + SA mammary tumor
cells after a 3-day culture period. +SA cells were seeded on 4-chamber culture slides at a density of 1x105 cells/chamber (3 replicates/group) and
allowed to attach overnight. Cells were then washed with PBS and incubated with vehicle control or treatment defined media containing 10 ng/ml
HGF for 3 days in culture. At the end of treatments, cells were fixed with 4% formaldehyde/PBS and permeabilized with 0.2% triton X-100. Fixed cells
were blocked and incubated with specific primary antibodies followed by incubation with Alexa Fluor 594- or 488-conjugated secondary antibodies.
Red or green color indicates positive fluorescence staining for target proteins, while blue color represents nuclear counter staining with DAPI. Magnification
is 200X. Figure obtained from reference 25 with permission.
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It has become increasingly evident during the past dec-
ade that HGF-dependent Met activation and signalingplays a major role in malignant progression and metasta-
sis. As a result, substantial interest has focused on deve-
loping therapeutic strategies that target the HGF/Met
Figure 5 δ-Tocotrienol and its oxazine derivative on CoCl2-
induced hypoxia and HIF-1α expression in mammary tumor cells.
HIF-1α is a hypoxia-inducible transcription factor that subsequently acts
to stimulate blood vessel formation and promote survival of cancer
cells during hypoxic conditions. (A) Effects of 150 μM CoCl2 (hypoxic,
but not cytotoxic dose) alone and in combination with non-growth
inhibitory doses (2 μM) of δ-tocotrienol or the δ-tocotrienol oxazine
derivative, 12-((R)-6,8-dimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,
11-trienyl)-9,10-dihydrochromeno[5,6-e] [1,3]oxazin-2(1H,3H,8H)-yl)
dodecan-1-ol), on HIF-1α levels in + SA mammary tumor cells.
Non-growth inhibitory doses of δ-tocotrienol and its oxazine derivative
were selected because high doses of these agents were found to initiate
apoptosis and induce cancer cell death, which would confound the
interpretation of the results regarding the effects of these agents on
tumor cell compensatory response to CoCl2 hypoxia. +SA cells were
seeded at concentration of 1.5X106 in 100 mm culture dishes and
allowed to attach overnight. The following day, cells were divided
into groups and exposed to their respective treatments for a 24 hr
incubation period. Afterwards, whole cell lysates were prepared for
Western blot analysis. (B) Scanning densitometric analysis was performed
on all blots done in triplicate and the integrated optical density of each
band was normalized with corresponding α-tubulin, as shown in the bar
graphs below their respective Western blot image. Vertical bars indicate
the normalized integrated optical density of bands visualized in each
lane ± SEM. #P< 0.05 compared to the vehicle-treated control group.
*P< 0.05 as compared to the hypoxic group treated with CoCl2 alone.
This figure was obtained from reference 65 with permission.
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one or more of the components within this signaling path-
way. Although the majority of research conducted in this
area has focused on preclinical studies using cell culture
and animal experimental models, a great number of thera-
peutic agents (onartuzumab, rilotumumab, tivantinib, and
cabozantinib) developed and refined in preclinical experi-
ments are increasingly the subject of clinical trials. Ther-
apies that disrupt cancer cell proliferation, survival,
motility, angiogenesis, invasion and metastasis will provide
great benefits in the treatment and cure of cancers thatdisplay aberrant Met activity. Recent evidence suggest that
γ-tocotrienol may also provide some benefit in the treat-
ment of breast cancers that displays Met dysregulation.
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